Cellular Islet Autoimmunity Associates with Clinical Outcome of Islet Cell Transplantation

Background Islet cell transplantation can cure type 1 diabetes (T1D), but only a minority of recipients remains insulin–independent in the following years. We tested the hypothesis that allograft rejection and recurrent autoimmunity contribute to this progressive loss of islet allograft function. Methodology/Principal Findings Twenty-one T1D patients received cultured islet cell grafts prepared from multiple donors and transplanted under anti-thymocyte globulin (ATG) induction and tacrolimus plus mycophenolate mofetil (MMF) maintenance immunosuppression. Immunity against auto- and alloantigens was measured before and during one year after transplantation. Cellular auto- and alloreactivity was assessed by lymphocyte stimulation tests against autoantigens and cytotoxic T lymphocyte precursor assays, respectively. Humoral reactivity was measured by auto- and alloantibodies. Clinical outcome parameters - including time until insulin independence, insulin independence at one year, and C-peptide levels over one year- remained blinded until their correlation with immunological parameters. All patients showed significant improvement of metabolic control and 13 out of 21 became insulin-independent. Multivariate analyses showed that presence of cellular autoimmunity before and after transplantation is associated with delayed insulin-independence (p = 0.001 and p = 0.01, respectively) and lower circulating C-peptide levels during the first year after transplantation (p = 0.002 and p = 0.02, respectively). Seven out of eight patients without pre-existent T-cell autoreactivity became insulin-independent, versus none of the four patients reactive to both islet autoantigens GAD and IA-2 before transplantation. Autoantibody levels and cellular alloreactivity had no significant association with outcome. Conclusions/Significance In this cohort study, cellular islet-specific autoimmunity associates with clinical outcome of islet cell transplantation under ATG-tacrolimus-MMF immunosuppression. Tailored immunotherapy targeting cellular islet autoreactivity may be required. Monitoring cellular immune reactivity can be useful to identify factors influencing graft survival and to assess efficacy of immunosuppression. Trial Registration Clinicaltrials.gov NCT00623610

[1]  M. V. von Herrath,et al.  Immunotherapy for the Prevention and Treatment of Type 1 Diabetes , 2009, Diabetes Care.

[2]  M. Côrrea-Giannella,et al.  Pancreatic islet transplantation , 2009, Diabetology & metabolic syndrome.

[3]  Constant Beckers.  The search for the Holy Grail , 2007 .

[4]  C. Mathieu,et al.  Correlation between β cell mass and glycemic control in type 1 diabetic recipients of islet cell graft , 2006, Proceedings of the National Academy of Sciences.

[5]  Philippe Morel,et al.  International trial of the Edmonton protocol for islet transplantation. , 2006, The New England journal of medicine.

[6]  Emile de Heer,et al.  Integrin signaling via RGD peptides and anti-beta1 antibodies confers resistance to apoptosis in islets of Langerhans. , 2006, Diabetes.

[7]  J. Drijfhout,et al.  Autoreactive CD8 T cells associated with β cell destruction in type 1 diabetes , 2005 .

[8]  G. Marchal,et al.  Feasibility, Safety, and Efficacy of Percutaneous Transhepatic Injection of β-Cell Grafts , 2005 .

[9]  J. Drijfhout,et al.  Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Junchao Cai,et al.  Humoral theory of transplantation: further evidence. , 2005, Current opinion in immunology.

[11]  D. Roelen,et al.  Alloreactivity Against Repeated HLA Mismatches of Sequential Islet Grafts Transplanted in Non-Uremic Type 1 Diabetes Patients , 2005, Transplantation.

[12]  A. Shapiro,et al.  Five-year follow-up after clinical islet transplantation. , 2005, Diabetes.

[13]  C. Ricordi,et al.  Requirements for success in clinical islet transplantation. , 2005, Transplantation.

[14]  G. Marchal,et al.  Feasibility, safety, and efficacy of percutaneous transhepatic injection of beta-cell grafts. , 2005, Journal of vascular and interventional radiology : JVIR.

[15]  D. Harlan,et al.  Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. , 2004, The Journal of clinical investigation.

[16]  G. A. Fleming,et al.  Erratum: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: Report of an ADA workshop, 21-22 October 2001 (Diabetes (2004) 53 (250-264)) , 2004 .

[17]  J. Bluestone,et al.  Transplantation of Cultured Islets from Two‐Layer Preserved Pancreases in Type 1 Diabetes with Anti‐CD3 Antibody , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  G. A. Fleming,et al.  C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. , 2004, Diabetes.

[19]  A. Shapiro,et al.  Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. , 2004, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[20]  Bart O. Roep Dr..  The role of T-cells in the pathogenesis of Type 1 diabetes: From cause to cure , 2003, Diabetologia.

[21]  P. Carlsson,et al.  Graft vascular function after transplantation of pancreatic islets , 2002, Diabetologia.

[22]  E. Bonifacio,et al.  Autoantibody response to islet transplantation in type 1 diabetes. , 2001, Diabetes.

[23]  S. Martin,et al.  Development of type 1 diabetes despite severe hereditary B-cell deficiency. , 2001, The New England journal of medicine.

[24]  M. Atkinson,et al.  Type 1 diabetes: new perspectives on disease pathogenesis and treatment , 2001, The Lancet.

[25]  D. Sutherland,et al.  Pancreas Transplantation for Treatment of Diabetes Mellitus , 2001, World Journal of Surgery.

[26]  H. Kolb,et al.  Development of type 1 diabetes despite severe hereditary B lymphocyte deficiency: No pathogenic role of B lymphocytes , 2000 .

[27]  L. V. Van Gaal,et al.  High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry. , 2000, Diabetes care.

[28]  F. Andreelli,et al.  Evidence of recurrent type I diabetes following HLA-mismatched pancreas transplantation. , 2000, Diabetes & metabolism.

[29]  E. Bonifacio,et al.  Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes. , 2000, Diabetes.

[30]  M. Brendel,et al.  Islet autoantibodies as potential markers for disease recurrence in clinical islet transplantation , 2000, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[31]  Ames,et al.  Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen , 2000 .

[32]  Å. Lernmark,et al.  Tolerance to kidney allograft transplanted into Type I diabetic patients persists after in vivo challenge with pancreatic islet allografts that express repeated mismatches , 1999, Diabetologia.

[33]  Roep Bo.  Standardization of T-cell assays in Type I diabetes. Immunology of Diabetes Society T-cell Committee. , 1999 .

[34]  A. Naji,et al.  Prevention of autoimmune recurrence and rejection by adenovirus-mediated CTLA4Ig gene transfer to the pancreatic graft in BB rat. , 1999, Diabetes.

[35]  Å. Lernmark,et al.  Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. , 1999, Diabetes.

[36]  B. Roep.  Standardization of T-cell assays in Type I diabetes , 1999, Diabetologia.

[37]  P. Bingley,et al.  Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. , 1998, Diabetes.

[38]  Alexyz G. Aquino,et al.  Successful long-term kidney-pancreas transplants in diabetic patients with high C-peptide levels. , 1998, Transplantation.

[39]  K. Salmela,et al.  Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipient characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft , 1998, Diabetologia.

[40]  B. Hering,et al.  Progressive Islet Graft Failure Occurs Significantly Earlier in Autoantibody-Positive Than in Autoantibody-Negative IDDM Recipients of Intrahepatic Islet Allografts , 1997, Diabetes.

[41]  R. Slover,et al.  Prevention of type I diabetes and recurrent beta-cell destruction of transplanted islets. , 1997, Endocrine reviews.

[42]  P. Kuo,et al.  Prevention of autoimmune islet allograft destruction by engraftment of donor T cells. , 1997, Transplantation.

[43]  F. Reinholt,et al.  Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. , 1996, The New England journal of medicine.

[44]  B. Roep.  T-Cell Responses to Autoantigens in IDDM: The Search for the Holy Grail , 1996, Diabetes.

[45]  S. Arden,et al.  T-Cell Reactivity to β-Cell Membrane Antigens Associated With β-Cell Destruction in IDDM , 1995, Diabetes.

[46]  S. Arden,et al.  T-cell reactivity to beta-cell membrane antigens associated with beta-cell destruction in IDDM. , 1995, Diabetes.

[47]  E. Sercarz,et al.  Determinant spreading and the dynamics of the autoimmune T-cell repertoire. , 1993, Immunology today.

[48]  F. Claas,et al.  Determination of cytotoxic T-lymphocyte precursor frequencies using europium labeling as a nonradioactive alternative to labeling with chromium-51. , 1992, Human immunology.

[49]  C. Boitard,et al.  Limited Duration of Remission of Insulin Dependency in Children With Recent Overt Type I Diabetes Treated With Low-Dose Cyclosporin , 1990, Diabetes.

[50]  D. Sutherland,et al.  Recurrence of Disease in Pancreas Transplants , 1989, Diabetes.

[51]  L W Strijbosch,et al.  Computer aided design and evaluation of limiting and serial dilution experiments. , 1988, International journal of bio-medical computing.

[52]  S. Johnson,et al.  Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. , 1988, The New England journal of medicine.

[53]  G. Eisenbarth,et al.  Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. , 1985, Diabetes research.

[54]  A. Michael,et al.  Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. , 1985, Laboratory investigation; a journal of technical methods and pathology.

[55]  P. Terasaki,et al.  Significance of the positive crossmatch test in kidney transplantation. , 1969, The New England journal of medicine.